Surface Oncology, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lisa McGrath
- Full Time Employees
- 35
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Hampshire Street Cambridge MA United States of America 02139
- IPO Date
- Apr 19, 2018
- CIK
- 0001718108
- Website
- surfaceoncology.com
- Similar Companies
- Business
- Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation antibody therapies that target the tumor microenvironment. The company’s core products include investigational immunotherapies such as SRF388, a first-in-class antibody targeting interleukin-27 (IL-27) currently in Phase II clinical trials for liver and lung cancers, and SRF114, an antibody targeting CCR8+ regulatory T cells in solid tumors, in Phase I/II studies. Surface also pursues development programs targeting CD39, CD73, and CD47 pathways to enhance anti-tumor immune responses. The company operates primarily in the United States with headquarters in Cambridge, Massachusetts, and serves oncology patients through collaborations with major pharmaceutical partners. Recently, Surface Oncology was acquired by Coherus BioSciences in a strategic all-stock transaction completed in September 2023, valued at approximately $66.9 million. This acquisition strengthened Coherus’ immuno-oncology pipeline and balance sheet and allowed prioritization of competitively positioned clinical programs while reducing R&D spending. Post-acquisition, Surface Oncology continues clinical development of its key immunotherapy candidates, including ongoing Phase II trials of SRF388 in combination with other agents for hepatocellular carcinoma and lung cancer. The company also initiated clinical and preclinical research efforts on novel immuno-oncology targets such as SRF114, reflecting its commitment to emerging tumor microenvironment therapies. Founded in 2014, Surface Oncology has focused on innovative cancer therapies targeting both the innate and adaptive immune system arms within the tumor microenvironment to convert non-responsive tumors into immune-active ones. Partnering with biotechnology and pharmaceutical firms like GlaxoSmithKline and Novartis before the acquisition, Surface has leveraged its expertise in tumor immunology to build a diverse pipeline of immune-enhancing antibodies aimed at delivering transformative outcomes for cancer patients. Overall, Surface Oncology provides next-generation tumor microenvironment immunotherapies with a pipeline of antibody candidates targeting IL-27, CCR8, CD39, and other immune checkpoint pathways. Its recent acquisition by Coherus BioSciences marks a strategic expansion to advance these innovative treatments for solid tumors and liver cancers through late-stage clinical development and commercialization preparation. The company remains headquartered in Cambridge, Massachusetts.
Honeywell Aerospace runway safety technology selected by Aeromexico for intended deployment on more than 100 aircraft
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
Best Penny Stocks To Buy This Week? 3 To Watch Right Now
Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences
Surface Oncology stock rallies on all-stock acquisition by Coherus
Subsea Umbilicals, Risers, And Flow Lines (SURF) Market size to grow by USD 5.2 billion from 2022 to 2027, The surge in energy demand to drive the market growth – Technavio
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
Surface Oncology to Participate in Upcoming Investor Conferences
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
Trading Penny Stocks? Top Stock Market News for March 11th, 2022
Why Surface Oncology (SURF) Might Surprise This Earnings Season
Surface Oncology, Inc. (SURF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings